Lemzoparlimab
Lemzoparlimab (TJ011133; TJC4) is a humanized anti-CD47 IgG4 antibody. Lemzoparlimab has a strong anti-tumor activity[1].
Product Specifications
CAS Number
[2377483-71-9]
Product Name Alternative
TJ011133; TJC4
UNSPSC
12352203
Target
CD47
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/lemzoparlimab.html
Purity
99.31
Solubility
H2O
Smiles
[Lemzoparlimab]
Molecular Weight
(145.58 kDa)
References & Citations
[1]Amitkumar Mehta, et al. Lemzoparlimab, a Differentiated Anti-CD47 Antibody in Combination with Rituximab in Relapsed and Refractory Non-Hodgkin's Lymphoma: Initial Clinical Results. Blood (2021) 138 (Supplement 1) : 3542.|[2]Jiang Z, et al., Targeting CD47 for cancer immunotherapy. J Hematol Oncol. 2021 Oct 30;14 (1) :180.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 2
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS1280222-01 0.02 mg (E-Coli)
Recombinant Influenza A virus Non-structural protein 1 (NS)
Ask
View Details 
MBS1280222-02 0.1 mg (E-Coli)
Recombinant Influenza A virus Non-structural protein 1 (NS)
Ask
View Details 
MBS1280222-03 0.02 mg (Yeast)
Recombinant Influenza A virus Non-structural protein 1 (NS)
Ask
View Details MBS1280222-04 0.1 mg (Yeast)
Recombinant Influenza A virus Non-structural protein 1 (NS)
Ask
View Details